Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 118

1.

Phase I Designs that Allow for Uncertainty in the Attribution of Adverse Events.

Iasonos A, O'Quigley J.

J R Stat Soc Ser C Appl Stat. 2017 Nov;66(5):1015-1030. doi: 10.1111/rssc.12195. Epub 2016 Nov 7.

PMID:
29085158
2.

Time to publication of oncology trials and why some trials are never published.

Chapman PB, Liu NJ, Zhou Q, Iasonos A, Hanley S, Bosl GJ, Spriggs DR.

PLoS One. 2017 Sep 21;12(9):e0184025. doi: 10.1371/journal.pone.0184025. eCollection 2017.

3.

Surgical site infection reduction bundle in patients with gynecologic cancer undergoing colon surgery.

Schiavone MB, Moukarzel L, Leong K, Zhou QC, Afonso AM, Iasonos A, Roche KL, Leitao MM Jr, Chi DS, Abu-Rustum NR, Zivanovic O.

Gynecol Oncol. 2017 Oct;147(1):115-119. doi: 10.1016/j.ygyno.2017.07.010. Epub 2017 Jul 19.

PMID:
28734498
4.

A reconstructed melanoma data set for evaluating differential treatment benefit according to biomarker subgroups.

Satagopan JM, Iasonos A, Kanik JG.

Data Brief. 2017 May 5;12:667-675. doi: 10.1016/j.dib.2017.05.005. eCollection 2017 Jun.

5.

Clinical Trials in the Genomic Era.

Joffe E, Iasonos A, Younes A.

J Clin Oncol. 2017 Mar 20;35(9):1011-1017. doi: 10.1200/JCO.2016.70.8891. Epub 2017 Feb 13. Review.

6.

A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer.

Cowan RA, Eriksson AGZ, Jaber SM, Zhou Q, Iasonos A, Zivanovic O, Leitao MM Jr, Abu-Rustum NR, Chi DS, Gardner GJ.

Gynecol Oncol. 2017 May;145(2):230-235. doi: 10.1016/j.ygyno.2017.02.010. Epub 2017 Mar 9.

PMID:
28285846
7.

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.

Smyth LM, Monson KR, Jhaveri K, Drilon A, Li BT, Abida W, Iyer G, Gerecitano JF, Gounder M, Harding JJ, Voss MH, Makker V, Ho AL, Razavi P, Iasonos A, Bialer P, Lacouture ME, Teitcher JB, Erinjeri JP, Katabi N, Fury MG, Hyman DM.

Invest New Drugs. 2017 Mar 9. doi: 10.1007/s10637-017-0445-0. [Epub ahead of print]

PMID:
28281183
8.

Survival of Patients with Serous Uterine Carcinoma Undergoing Sentinel Lymph Node Mapping.

Schiavone MB, Scelzo C, Straight C, Zhou Q, Alektiar KM, Makker V, Soslow RA, Iasonos A, Leitao MM, Abu-Rustum NR.

Ann Surg Oncol. 2017 Jul;24(7):1965-1971. doi: 10.1245/s10434-017-5816-4. Epub 2017 Mar 3.

PMID:
28258415
9.

Measuring differential treatment benefit across marker specific subgroups: The choice of outcome scale.

Satagopan JM, Iasonos A.

Contemp Clin Trials. 2017 Feb 22. pii: S1551-7144(16)30093-3. doi: 10.1016/j.cct.2017.02.007. [Epub ahead of print]

PMID:
28254404
10.

A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.

Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Iyer RB, Zhou Q, Iasonos A, Denesopolis J, Zivanovic O, Long Roche KC, Sonoda Y, Coleman RL, Abu-Rustum NR, Hricak H, Chi DS.

Gynecol Oncol. 2017 Apr;145(1):27-31. doi: 10.1016/j.ygyno.2017.02.020. Epub 2017 Feb 14.

PMID:
28209497
11.

An efficient basket trial design.

Cunanan KM, Iasonos A, Shen R, Begg CB, Gönen M.

Stat Med. 2017 May 10;36(10):1568-1579. doi: 10.1002/sim.7227. Epub 2017 Jan 18.

PMID:
28098411
12.

Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer.

Schram AM, Iasonos A, Hyman DM.

J Clin Oncol. 2016 Dec 20;34(36):4312-4314. Epub 2016 Oct 23. No abstract available.

13.

Early phase dose finding methodology.

Iasonos A, O'Quigley J.

Stat Med. 2017 Jan 30;36(2):201-203. doi: 10.1002/sim.7155. No abstract available.

PMID:
27921353
14.

Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency.

Cunanan KM, Gonen M, Shen R, Hyman DM, Riely GJ, Begg CB, Iasonos A.

J Clin Oncol. 2017 Jan 20;35(3):271-273. doi: 10.1200/JCO.2016.69.9751. Epub 2016 Nov 28. No abstract available.

15.

Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.

Mueller JJ, Kelly A, Zhou Q, Iasonos A, Long Roche K, Sonoda Y, O'Cearbhaill RE, Zivanovic O, Chi DS, Gardner GJ.

Gynecol Oncol. 2016 Dec;143(3):496-503. doi: 10.1016/j.ygyno.2016.09.014. Epub 2016 Sep 28.

PMID:
27692668
16.

Dose expansion cohorts in Phase I trials.

Iasonos A, O'Quigley J.

Stat Biopharm Res. 2016;8(2):161-170. Epub 2016 Jun 2.

17.

Integrating the escalation and dose expansion studies into a unified Phase I clinical trial.

Iasonos A, O'Quigley J.

Contemp Clin Trials. 2016 Sep;50:124-34. doi: 10.1016/j.cct.2016.06.010. Epub 2016 Jul 5.

18.

Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker.

Iasonos A, Chapman PB, Satagopan JM.

Clin Cancer Res. 2016 May 1;22(9):2114-20. doi: 10.1158/1078-0432.CCR-15-2517.

19.

A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission.

O'Cearbhaill RE, Ragupathi G, Zhu J, Wan Q, Mironov S, Yang G, Spassova MK, Iasonos A, Kravetz S, Ouerfelli O, Spriggs DR, Danishefsky SJ, Sabbatini PJ.

Cancers (Basel). 2016 Apr 22;8(4). pii: E46. doi: 10.3390/cancers8040046.

20.

Dimension of model parameter space and operating characteristics in adaptive dose-finding studies.

Iasonos A, Wages NA, Conaway MR, Cheung K, Yuan Y, O'Quigley J.

Stat Med. 2016 Sep 20;35(21):3760-75. doi: 10.1002/sim.6966. Epub 2016 Apr 18.

Supplemental Content

Loading ...
Support Center